SCHEMBL843830

SCHEMBL843830

CC(C)(C)Oc1ccccc1[O]

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.38
CA1 P00915 3/20 0.38
CA2 P00918 3/20 0.38
CA7 P43166 2/20 0.38
CA9 Q16790 2/20 0.38
CA12 O43570 1/20 0.38
CA4 P22748 1/20 0.38
CA14 Q9ULX7 1/20 0.38
ALDH1A1 P00352 4/20 0.36
HSD17B10 Q99714 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ELANE P08246 3/20 0.35
TDP1 Q9NUW8 3/20 0.33
TSHR P16473 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.32
KIF11 P52732 1/20 0.32
HTR6 P50406 1/20 0.32
MAPT P10636 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
GLA P06280 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29428931 0.84 CA1 (0.45) KCNH2CA1CA2CA7CA9
SCHEMBL3820431 0.84 CA1 (0.45) KCNH2CA1CA2CA7CA9
SCHEMBL2046579 0.82 KCNH2 (0.38) KCNH2ALDH1A1HSD17B10KDM4E
Formaldehyde SCHEMBL28276257 0.82 CA1 (0.39) KCNH2CA1CA2CA7CA9
SCHEMBL9647568 0.80 KCNH2 (0.42) KCNH2CA1CA2CA7CA9
SCHEMBL12355661 0.77 CA12 (0.39) KCNH2CA1CA2CA7CA9
SCHEMBL28701701 0.77 CA1 (0.39) KCNH2CA1CA2CA7CA9
SCHEMBL8053750 0.76 CA1 (0.35) KCNH2CA1CA2CA7CA9
SCHEMBL364380 0.75 GAA (0.42) ALDH1A1KDM4EL3MBTL1NPSR1
SCHEMBL6933536 0.75 ALDH1A1 (0.46) KCNH2CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117831652-A Prediction method of olefin hydroformylation positive-to-negative ratio 上海华谊控股集团有限公司 2024-04-05 CN claimed
CN-117831652-A Prediction method of olefin hydroformylation positive-to-negative ratio 上海华谊控股集团有限公司 2024-04-05 CN disclosed
CN-110088164-B Epoxy resin composition DIC株式会社 2021-07-27 CN disclosed
EP-2597932-B1 MANUFACTURING METHOD FOR ORGANIC LIGHT-EMITTING DEVICE SUMITOMO CHEMICAL CO (JP) 2021-04-14 EP disclosed
EP-2680672-B1 METHOD FOR PRODUCING ORGANIC ELECTROLUMINESCENT ELEMENT SUMITOMO CHEMICAL CO (JP) 2021-03-31 EP disclosed
EP-2485289-B1 LAMINATED STRUCTURE, POLYMER, ELECTROLUMINESCENT ELEMENT, AND PHOTOELECTRIC CONVERSION ELEMENT SUMITOMO CHEMICAL CO (JP) 2021-03-03 EP disclosed
US-10862169-B2 Phosphorus electrolytic solution containing magnesium ions FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2020-12-08 US disclosed
EP-2605621-B1 ORGANIC ELECTROLUMINESCENT ELEMENT AND METHOD OF PRODUCING SAME SUMITOMO CHEMICAL CO (JP) 2020-07-15 EP disclosed
US-20200115543-A1 EPOXY RESIN COMPOSITION DIC CORPORATION (JP) 2020-04-16 US disclosed
EP-2846374-B1 Layered structure SUMITOMO CHEMICAL CO (JP) 2019-11-06 EP disclosed
US-7208567-B2 Polymer compound and polymer light emitting device using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-04-24 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed
US-20040002576-A1 Polymer compound and polymer light emitting device using the same SUMITOMO CHEMICAL COMPANY, LIMITED 2004-01-01 US disclosed
US-6627714-B2 Copolymerizing ethylene and dicyclopentadiene or tricyclopentadiene, and cyclic olefin in presence of metallocene catalyst to produce copolymer MARUZEN PETROCHEMICAL CO., LTD. (JP) 2003-09-30 US disclosed
EP-1344788-A1 Conjugated polymer comprising dibenzothiophene- or dibenzofuran-units and their use in polymer LEDs SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-09-17 EP disclosed
US-20020058767-A1 Method for producing an olefin type copolymer having a cyclic structure MARUZEN PETROCHEMICAL CO., LTD. (JP) 2002-05-16 US disclosed
EP-1205497-A2 Method for producing an olefin type copolymer having a cyclic structure MARUZEN PETROCHEMICAL CO., LTD. (JP) 2002-05-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KCNH2 3503/4885CA1 3493/4885CA2 1853/4885
US-10862169-B2 Phosphorus electrolytic solution containing magnesium ions PEF1, RER1, AFF1 KCNH2 80/4885CA1 74/4885CA2 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.